Candriam SCA’s Tandem Diabetes Care TNDM Stock Holding History

Candriam SCA’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-36,587	Closed	-$898K	–	689
2023 Q2	$898K	Hold	36,587	–	–	0.01%	619
2023 Q1	$1.37M	Buy	36,587 +18,000	+97%	+$745K	0.01%	649
2022 Q4	$835K	Sell	18,587 -23,988	-56%	-$1.09M	0.01%	738
2022 Q3	$2.04M	Sell	42,575 -81,499	-66%	-$4.47M	0.01%	582
2022 Q2	$7.34M	Buy	124,074 +81,499	+191%	+$6.69M	0.06%	272
2022 Q1	$4.95M	Buy	42,575 +6,887	+19%	+$804K	0.03%	350
2021 Q4	$5.37M	Buy	35,688 +101	+0.3%	+$13.6K	0.03%	352
2021 Q3	$4.25M	Sell	35,587 -38,000	-52%	-$4.19M	0.03%	424
2021 Q2	$7.17M	Buy	73,587 +21,217	+41%	+$1.89M	0.05%	335
2021 Q1	$4.81M	Hold	52,370	–	–	0.04%	379
2020 Q4	$5.01M	Buy	52,370 +20,370	+64%	+$2.1M	0.04%	388
2020 Q3	$3.63M	Sell	32,000 -3,000	-9%	-$315K	0.03%	403
2020 Q2	$3.46M	Buy	+35,000	New	+$2.79M	0.04%	402

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Candriam SCA's TNDM Position: Q3 2023 in Review

Candriam SCA sold out of Tandem Diabetes Care (TNDM) in Q3 2023, closing a stake of 36,587 shares — an estimated $898K sold.

Candriam SCA first reported a position in TNDM in Q2 2020 and held it in 13 quarters. The position peaked at $7.34M in Q2 2022. 226 funds tracked by Wall St. Rank hold TNDM as of Q3 2023.

Candriam SCA reported no remaining Tandem Diabetes Care position as of Q3 2023 after selling out during the quarter.
Candriam SCA sold 36,587 Tandem Diabetes Care shares in Q3 2023, an estimated $898K.
Candriam SCA first reported a position in Tandem Diabetes Care in Q2 2020 and held it in 13 quarters.
Candriam SCA's Tandem Diabetes Care position peaked at $7.34M in Q2 2022.
226 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2023.

Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.